Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReSPECT study of rezafungin versus standard antimicrobial prophylaxis after allogeneic blood and marrow transplantation
NL-OMON49120Phase 3Withdrawn
- Sponsor
- Cidara Therapeutics
- Start
- Jan 2020
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rezafungin in invasive mycoses (2 arms), sponsored by Cidara Therapeutics. Primary endpoint: Primary efficacy endpoint. Planned start Jan 2020; status: withdrawn.
02
Drugs
rezafungin
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on NL-OMON49120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49120.